Stefan Traussnigg
Overview
Explore the profile of Stefan Traussnigg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paternostro R, Staufer K, Traussnigg S, Stattermayer A, Halilbasic E, Keritam O, et al.
Hepatol Int
. 2021 Jun;
15(4):922-933.
PMID: 34076851
Objective: Several single-nucleotide polymorphisms have been identified to be disadvantageous or protective in regard to disease severity in patients with non-alcoholic fatty liver disease (NAFLD). However, it is unclear, whether...
2.
Paternostro R, Traussnigg S, Staufer K, Mandorfer M, Halilbasic E, Lagler H, et al.
Hepatol Res
. 2020 Oct;
51(1):69-79.
PMID: 33037853
Aim: In most immune-competent individuals, hepatitis E (HEV) infections appear silent. It is unclear whether past HEV infections deteriorate disease severity in patients with non-alcoholic fatty liver disease (NAFLD). Methods:...
3.
Traussnigg S, Halilbasic E, Hofer H, Munda P, Stojakovic T, Fauler G, et al.
Wien Klin Wochenschr
. 2020 Sep;
133(9-10):441-451.
PMID: 32930860
Background: The PX-104 is an oral non-steroidal agonist for the farnesoid X receptor (FXR), a key regulator of bile acid (BA), glucose and lipid homeostasis. Aims And Methods: This single...
4.
Smajis S, Gajdosik M, Pfleger L, Traussnigg S, Kienbacher C, Halilbasic E, et al.
Am J Clin Nutr
. 2019 Dec;
111(2):369-377.
PMID: 31796953
Background: Increased fructose intake has been associated with metabolic consequences such as impaired hepatic lipid metabolism and development of nonalcoholic fatty liver disease (NAFLD). Objectives: The aim of this study...
5.
Traussnigg S, Schattenberg J, Demir M, Wiegand J, Geier A, Teuber G, et al.
Lancet Gastroenterol Hepatol
. 2019 Jul;
4(10):781-793.
PMID: 31345778
Background: Norursodeoxycholic acid is an orally administered side chain-shortened homologue of ursodeoxycholic acid that undergoes hepatic enrichment with hepatoprotective, anti-inflammatory, and antifibrotic activity. We assessed the efficacy of two doses...
6.
Traussnigg S, Kienbacher C, Gajdosik M, Valkovic L, Halilbasic E, Stift J, et al.
Liver Int
. 2017 May;
37(10):1544-1553.
PMID: 28544208
Background & Aims: With the rising prevalence of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) non-invasive tools obtaining pathomechanistic insights to improve risk stratification are urgently needed. We therefore...
7.
Stattermayer A, Traussnigg S, Aigner E, Kienbacher C, Huber-Schonauer U, Steindl-Munda P, et al.
J Trace Elem Med Biol
. 2016 Dec;
39:100-107.
PMID: 27908400
Introduction: The pathogenesis of non-alcoholic fatty liver disease (NAFLD) is multifactorial including metabolic, genetic (e.g. PNPLA3 [patatin-like phospholipase domain-containing 3 gene]), viral factors and drugs. Besides, there is evidence for...
8.
Luger M, Kruschitz R, Kienbacher C, Traussnigg S, Langer F, Prager G, et al.
Obes Surg
. 2016 Nov;
27(5):1196-1207.
PMID: 27837387
Background: Bariatric patients often suffer from vitamin D deficiency (VDD), and both, morbid obesity and VDD, are related to non-alcoholic fatty liver disease. However, limited data are available regarding best...
9.
Halilbasic E, Fuchs C, Traussnigg S, Trauner M
Dig Dis
. 2016 Jun;
34(5):580-8.
PMID: 27332721
The intracellular nuclear receptor farnesoid X receptor (FXR) and the transmembrane G protein-coupled receptor 5 (TGR5) respond to bile acids (BAs) by activating transcriptional networks and/or signaling cascades. These cascades...
10.
Luger M, Kruschitz R, Kienbacher C, Traussnigg S, Langer F, Schindler K, et al.
Obes Surg
. 2016 Mar;
26(10):2425-32.
PMID: 26989059
Background: Morbidly obese patients are at risk for non-alcoholic fatty liver disease (NAFLD) and vitamin D deficiency (VDD). Non-alcoholic steatohepatitis (NASH) is the progressive variant of NAFLD and can advance...